Based on currently available data and expert opinions, a research and advisory firm projects that the next decade will witness triple and quadruple therapies as the gold standard for treating Hepatitis C.<\/p>\n
In 2013, the Telaprevir\/peg-IFN-a-2a\/ribavirin Regimen Will Earn Decision Resources’ Proprietary Clinical Gold Standard for Hepatitis C Virus Treatment-Naive Patients<\/p>\n
In 2018, a Quadruple Therapy Regimen Will Likely Be Widely Used for the Treatment-Naive Patient Population, According to a New Report from Decision Resources<\/p>\n
WALTHAM, Mass., March 25 \/PRNewswire\/ — Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on available data and expert opinion, the telaprevir\/peg-IFN-a-2a\/ribavirin* regimen will earn Decision Resources proprietary clinical gold-standard status for the treatment of hepatitis C virus (treatment-naive population) in 2013, following telaprevir’s approval for the indication in 2011.<\/p>\n
The telaprevir\/peg-IFN-a-2a\/ribavirin regimen will earn gold standard status in 2013 owing to its competitive advantages in efficacy and delivery over all currently available hepatitis C virus therapies. In 2009, Decision Resources’ clinical gold standard for hepatitis C virus (treatment-naive population) was peg-IFN-a-2a\/ribavirin.<\/p>\n